1-3 of 3
Bochra Sedaki
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Poor Prognosis of SRSF2 Gene Mutations in Patients Treated with Venetoclax-Azacitidine (VEN-AZA) for Newly Diagnosed Acute Myeloid Leukemia. a Multicentric Real-Life Study of 117 Patients

Guillaume Berton, Bochra Sedaki, Erwann Collomb, Sami Benachour, Michael Loschi, Bilal Mohty, Colombe Saillard, Yosr Hicheri, Camille Rouzaud, Valerio Maisano, Ferdinand Villetard, Evelyne D'Incan Corda, Aude Charbonnier, Jerome Rey, Marie Anne Hospital, Antoine Ittel, Norman Abbou, Raphaelle Fanciullino, Bérengère Dadone-Montaudié, Norbert Vey, Geoffroy Venton, Thomas Cluzeau, Anne Sophie Alary, Sylvain Garciaz
Journal: Blood
Blood (2023) 142 (Supplement 1): 2848.
https://doi.org/10.1182/blood-2023-180733
Published: 2023
Journal Articles

Allogenic Stem Cell Transplant in Myelofibrosis: Comparison of Two Tapering Strategies of Immunosuppressive Agents

Ghada Abichou, Bochra Sedaki, Sami Benachour, Thomas Cluzeau, Michael Loschi
Journal: Blood
Blood (2023) 142 (Supplement 1): 7083.
https://doi.org/10.1182/blood-2023-184424
Published: 2023
Journal Articles

Unmodified Dose of Azacitidine Plus Venetoclax Regimen without Drug Interactions during the First Cycle Leads to Similar Outcomes between Viale-a Clinical Trial and Real-Life in Acute Myeloid Leukemia

Bochra Sedaki, Alexandre Iat, Michael Loschi, Sami Benachour, Edmond Chiche, Lea Ryffel, Patricia Brugel, Isabelle Sudaka, Danièle Aquaronne, Corinne Ferrero, Berengere Dadone, Thomas Cluzeau
Journal: Blood
Blood (2022) 140 (Supplement 1): 11718–11719.
https://doi.org/10.1182/blood-2022-164608
Published: 2022